Assembly Biosciences, Inc. (ASMB:NASDAQ) closed at $20.52 on October 22, 2026, up 0.29% on the day. The stock trades 48.3% below its 52-week high of $39.71 and 2.9% above its 52-week low of $19.94. Over the past year, it lost 27.3%. Assembly Biosciences, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 21, 2025, ASMB closed higher on 127 days (50%). Its best day was February 20, 2026 (+10.70%) and its worst was October 13, 2026 (-10.67%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 3 times.
Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its lead product candidate from the platform is AB-M101 that has been completed Phase Ia clinical trial to treat clostridium difficile infections. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Find more stocks like ASMB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.